Enterprise Value
350.8M
Cash
88.2M
Avg Qtr Burn
-6.10M
Short % of Float
7.27%
Insider Ownership
13.22%
Institutional Own.
51.23%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
YUTREPIA (Treprostinil) (LIQ861) Details Rare diseases, Pulmonary arterial hypertension, Lung disease, Pulmonary hypertension associated with interstitial lung disease | Approved Update | |
YUTREPIA (Treprostinil) (LIQ861) Details Rare diseases, Pulmonary hypertension associated with interstitial lung disease, Pulmonary arterial hypertension, Lung disease | PDUFA Approval decision | |
L606 Details Pulmonary hypertension associated with interstitial lung disease, Pulmonary arterial hypertension | Phase 3 Initiation | |
LIQ865 Details Post-surgical pain | Failed Discontinued |